Skip directly to site content Skip directly to page options Skip directly to A-Z link


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
															Search

		Submit


Sexually Transmitted Diseases (STDs)


Facebook
        Twitter
        LinkedIn
        Syndicate





Clinical Advisory: Ocular Syphilis in the United States										Related Pages
										**Updated March 24, 2016**
Between December 2014 and March 2015, 12 cases of ocular syphilis were reported from two major cities, San Francisco and Seattle. Subsequent case finding indicated more than 200 cases reported over the past 2 years from 20 states. The majority of cases have been among HIV-infected MSM; a few cases have occurred among HIV-uninfected persons including heterosexual men and women. Several of the cases have resulted in significant sequelae including blindness.
Ocular syphilis can involve almost any eye structure, but posterior uveitis and panuveitis are the most common. Additional manifestations may include anterior uveitis, optic neuropathy, retinal vasculitis and interstitial keratitis. Ocular syphilis may lead to decreased visual acuity including permanent blindness. Ocular syphilis can be associated with neurosyphilis. Both ocular syphilis and neurosyphilis can occur at any stage of syphilis, including primary and secondary syphilis. While previous research supports evidence of neuropathogenic strains of syphilis, it remains unknown if some *Treponema pallidum* strains have a greater likelihood of causing ocular infections.
**Clinicians should be aware of ocular syphilis and screen for visual complaints in any patient at risk for syphilis** (MSM, HIV-infected persons, others with risk factors and persons with multiple or anonymous partners).
**All patients with syphilis should receive an HIV test if status is unknown or previously HIV-negative**
**Patients with positive syphilis serology and early syphilis without ocular symptoms should receive a careful neurological exam including all cranial nerves.**
**Patients with syphilis and ocular complaints should receive immediate ophthalmologic evaluation.**
**A lumbar puncture with cerebrospinal fluid (CSF) examination should be performed in patients with syphilis and ocular complaints.**
**Ocular syphilis should be managed according to treatment recommendations for neurosyphilis**
**Cases of ocular syphilis should be reported to your state or local health department within 24 hours of diagnosis. Ocular syphilis cases diagnosed since December 1, 2014,** **should be reported to your local or state health department.**The case definition for an ocular syphilis case is as follows: a person with clinical symptoms or signs consistent with ocular disease (i.e. uveitis, panuveitis, diminished visual acuity, blindness, optic neuropathy, interstitial keratitis, anterior uveitis, and retinal vasculitis) with syphilis of any stage.**Pre-antibiotic clinical samples (whole blood in EDTA tubes, primary lesions and moist secondary lesions, CSF or ocular fluid) should be saved and stored at -80°C immediately upon collection for molecular typing.**
**If you are a healthcare provider and need advice from CDC regarding the clinical management of ocular syphilis, contact Dr. Kimberly Workowski at 404-639-1898 or kgw2@cdc.gov. If you are planning on collecting clinical specimens for molecular typing and need assistance with the collection procedure or shipment of samples, please contact Dr. Allan Pillay at 404-639-2140 orajp7@cdc.gov.**
Related Content
Ocular Syphilis — Eight Jurisdictions, United States, 2014–2015 MMWR November 4, 2016
Keep an Eye Out For Ocular Syphilisexternal icon – Tom Peterman, MD, MSc; Kimberly Workowski, MD discuss the recent increase in ocular syphilis cases and provide physicians with information on diagnosis and treatment in this Medscape CDC Expert Commentary (Requires free membership to access commentary) (February 8, 2016)
Notes from the Field: A Cluster of Ocular Syphilis Cases — Seattle, Washington, and San Francisco, California, 2014–2015 MMWR October 16, 2015 *(Please follow your state or county health department’s guidance for reporting clinical manifestations of cases of syphilis.)*
							
					
						Page last reviewed:  March 25, 2020					Content source: 	Division of STD Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention homeSyphilis
Facts & Brochuresplus icon
Basic Fact Sheet
Detailed Fact Sheet
Congenital Syphilis Fact Sheet
Syphilis & MSM Fact Sheet
Syphilis Images
Statistics
Laboratory Information
Treatment and Care
What You Can Doplus icon
What Healthcare Providers Can Do
What Gay and Bisexual Men Can Do
What Pregnant Women Can Do
Other Resources
Archive


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue